BioSpace News Archive

ProMIS Neurosciences Inc. (Nasdaq: PMN) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its first quarter fiscal year 2024 for the period ended September 30, 2023.

Alcon, the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

Disc Medicine, Inc. (NASDAQ:IRON) today announced that the United States Patent and Trademark Office (USPTO) has issued patent No. 11,813,257 for methods of treating erythropoietic protoporphyrias (EPPs) with glycine transport inhibitors.

Penumbra, Inc. announced that its management team is scheduled to present at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023.

Biohaven Ltd. reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference in Miami, FL.

HeartBeam, Inc. has reported its financial and operational results for the third quarter ended September 30, 2023.

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update.